Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Envoy Medical, Inc.COCH · Entity 7161 | Director | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Envoy Medical, Inc.
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 174,037 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Purchase · Acquired 96,150 · Balance 174,037 |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 57,690 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Purchase · Acquired 57,690 · Balance 57,690 F2: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 96,150 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Purchase · Acquired 96,150 · Balance 96,150 F2: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-10-15 | Direct | 62,500 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 62,500 F1: Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2035-12-03 | Direct | 62,500 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 62,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
F3: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F4: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIONBRIDGE TECHNOLOGIES INC /DE/
Report date February 28, 2017 · Filed March 02, 2017
Section 16 reporting ended · disclosed 2017-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2021-07-18 | Direct | 0 |
Reported balance
After 2017-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-28 · Disposition to issuer · Disposed 27,353 · Balance 0 F1: Immediately prior to the effective time of the Merger, each Lionbridge option, whether or not vested and exercisable, outstanding and unexercised immediately prior to the effective time was converted into the right to receive an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $5.75 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. ("Lionbridge") and entities affiliated with H.I.G. Capital, LLC (the "Merger Agreement"). The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the "Merger"). |
| restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-08-18 | Direct | 0 |
Reported balance
After 2017-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-28 · Disposition to issuer · Disposed 7,559 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. ("Lionbridge") and entities affiliated with H.I.G. Capital, LLC (the "Merger Agreement"). The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the effective time of the Merger, each Lionbridge option, whether or not vested and exercisable, outstanding and unexercised immediately prior to the effective time was converted into the right to receive an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $5.75 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. ("Lionbridge") and entities affiliated with H.I.G. Capital, LLC (the "Merger Agreement"). The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the "Merger").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 17, 2026 16:47 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 96,150 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000026 · form4.xml · derivative · entry 5 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,150 Underlying: Class A Common Stock · 96,150 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:47 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 57,690 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000026 · form4.xml · derivative · entry 4 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,690 Underlying: Class A Common Stock · 57,690 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:47 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 96,150 | $0.40 | $38,460.00 |
DisclosureSEC source: 0000914190-26-000026 · form4.xml · nonDerivative · entry 1 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,037 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:40 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000049 · form4.xml · derivative · entry 3 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 62,500 shares Expires 2035-12-03 Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 17:52 UTC | Envoy Medical, Inc. COCH · Entity 7161 | OtherClass A Common Stock | 34,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-050422 · form4.xml · nonDerivative · entry 1 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,887 F1 · kind: These shares were received by the reporting person in connection with a pro-rata distribution in-kind by Anzu SPAC GP I LLC to its members for no consideration. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 18:04 UTC | Envoy Medical, Inc. COCH · Entity 7161 | OtherClass A Common Stock | 18,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-019530 · form4.xml · nonDerivative · entry 1 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,182 F1 · kind: These shares were received by the reporting person in connection with a pro-rata distribution in-kind by Anzu SPAC GP I LLC to its members for no consideration. Read SEC document |
| October 15, 2023 Filed Oct 17, 2023 17:29 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001062993-23-019481 · form4.xml · derivative · entry 2 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 62,500 shares Expires 2033-10-15 F1 · price: Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. F1 · derivative.exercise_date: Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 21:50 UTC | Envoy Medical, Inc. COCH · Entity 7161 | ConversionClass B Common Stock, par value $0.0001 per share · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-018935 · form4.xml · derivative · entry 2 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock, par value $0.0001 per share · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. F1 · kind: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. F1 · price: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. F1 · derivative.exercise_date: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. F1 · derivative.expiration_date: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. F1 · balance_after: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 21:50 UTC | Envoy Medical, Inc. COCH · Entity 7161 | ConversionClass A Common Stock, par value $0.0001 per share | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-018935 · form4.xml · nonDerivative · entry 1 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 15:43 UTC | LIONBRIDGE TECHNOLOGIES INC /DE/ LIOX · Entity 178276 | Disposition to issuerrestricted stock units · Derivative | 7,559 | $5.75 Strike: $0.00 | $43,464.25 |
DisclosureSEC source: 0001328319-17-000027 · edgar.xml · derivative · entry 2 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 7,559 shares Expires 2017-08-18 F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. ("Lionbridge") and entities affiliated with H.I.G. Capital, LLC (the "Merger Agreement"). The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the "Merger"). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 15:43 UTC | LIONBRIDGE TECHNOLOGIES INC /DE/ LIOX · Entity 178276 | Disposition to issuerstock option (right to buy) · Derivative | 27,353 | $1.12 Strike: $4.63 | $30,635.36 |
DisclosureSEC source: 0001328319-17-000027 · edgar.xml · derivative · entry 1 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 27,353 shares Expires 2021-07-18 F1 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each Lionbridge option, whether or not vested and exercisable, outstanding and unexercised immediately prior to the effective time was converted into the right to receive an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $5.75 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. ("Lionbridge") and entities affiliated with H.I.G. Capital, LLC (the "Merger Agreement"). The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the "Merger"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.